|
US6134717A
(en)
|
1998-11-20 |
2000-10-24 |
Morning Pride Manufacturing, L.L.C. |
Protective garment with leg portions and with cuffs to prevent liquids from entering boots
|
|
ATE490267T1
(de)
|
2001-06-05 |
2010-12-15 |
Curevac Gmbh |
Stabilisierte mrna mit erhöhtem g/c-gehalt, kodierend für ein virales antigen
|
|
DE10162480A1
(de)
|
2001-12-19 |
2003-08-07 |
Ingmar Hoerr |
Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
|
|
US7901708B2
(en)
|
2002-06-28 |
2011-03-08 |
Protiva Biotherapeutics, Inc. |
Liposomal apparatus and manufacturing methods
|
|
US10188083B2
(en)
|
2016-08-21 |
2019-01-29 |
Daniel Michael Leo |
Insect production systems and methods
|
|
DE10229872A1
(de)
|
2002-07-03 |
2004-01-29 |
Curevac Gmbh |
Immunstimulation durch chemisch modifizierte RNA
|
|
DE10335833A1
(de)
|
2003-08-05 |
2005-03-03 |
Curevac Gmbh |
Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
|
|
US20090104226A1
(en)
|
2004-05-21 |
2009-04-23 |
Novartis Vaccines And Diagnostics Inc. |
Alphavirus Vectors for Respiratory Pathogen Vaccines
|
|
JP2008505114A
(ja)
|
2004-06-30 |
2008-02-21 |
アイディー バイオメディカル コーポレイション オブ ケベック |
コロナウイルス感染を処置するためのワクチン組成物
|
|
DE102004042546A1
(de)
|
2004-09-02 |
2006-03-09 |
Curevac Gmbh |
Kombinationstherapie zur Immunstimulation
|
|
DE102005023170A1
(de)
|
2005-05-19 |
2006-11-23 |
Curevac Gmbh |
Optimierte Formulierung für mRNA
|
|
EP3611266B1
(en)
|
2005-08-23 |
2022-11-09 |
The Trustees of the University of Pennsylvania |
Rna containing modified nucleosides and methods of use thereof
|
|
DE102005046490A1
(de)
|
2005-09-28 |
2007-03-29 |
Johannes-Gutenberg-Universität Mainz |
Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
|
|
EP2049665A2
(en)
|
2006-07-28 |
2009-04-22 |
Applera Corporation |
Dinucleotide mrna cap analogs
|
|
DE102006035618A1
(de)
|
2006-07-31 |
2008-02-07 |
Curevac Gmbh |
Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
|
|
DE102006061015A1
(de)
|
2006-12-22 |
2008-06-26 |
Curevac Gmbh |
Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
|
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
|
WO2008157688A2
(en)
|
2007-06-19 |
2008-12-24 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap
|
|
WO2009030254A1
(en)
|
2007-09-04 |
2009-03-12 |
Curevac Gmbh |
Complexes of rna and cationic peptides for transfection and for immunostimulation
|
|
WO2009046738A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
|
|
WO2009046739A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating prostate cancer (pca)
|
|
EP2176408B9
(en)
|
2008-01-31 |
2015-11-11 |
Curevac GmbH |
NUCLEIC ACIDS COMPRISING FORMULA (NuGiXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
|
|
NZ589157A
(en)
|
2008-04-14 |
2013-06-28 |
Corp Nuvolt Inc |
Detecting electrical anomalies by receiving sensor data with received anomaly detection rules
|
|
AU2009238175C1
(en)
|
2008-04-15 |
2023-11-30 |
Arbutus Biopharma Corporation |
Novel lipid formulations for nucleic acid delivery
|
|
PL215513B1
(pl)
|
2008-06-06 |
2013-12-31 |
Univ Warszawski |
Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
|
|
WO2010037408A1
(en)
|
2008-09-30 |
2010-04-08 |
Curevac Gmbh |
Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
|
|
US20110300205A1
(en)
|
2009-07-06 |
2011-12-08 |
Novartis Ag |
Self replicating rna molecules and uses thereof
|
|
EP2281579A1
(en)
|
2009-08-05 |
2011-02-09 |
BioNTech AG |
Vaccine composition comprising 5'-Cap modified RNA
|
|
US20110053829A1
(en)
|
2009-09-03 |
2011-03-03 |
Curevac Gmbh |
Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
|
|
CA2816925C
(en)
|
2009-11-04 |
2023-01-10 |
The University Of British Columbia |
Nucleic acid-containing lipid particles and related methods
|
|
HUE042177T2
(hu)
|
2009-12-01 |
2019-06-28 |
Translate Bio Inc |
Szteroidszármazék mRNS szállítására humán genetikai betegségekben
|
|
KR20240136456A
(ko)
|
2009-12-07 |
2024-09-13 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
세포 리프로그래밍을 위한 정제된 변형 ｒｎａ를 포함하는 ｒｎａ 제제
|
|
WO2011069529A1
(en)
|
2009-12-09 |
2011-06-16 |
Curevac Gmbh |
Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
|
|
WO2011076807A2
(en)
|
2009-12-23 |
2011-06-30 |
Novartis Ag |
Lipids, lipid compositions, and methods of using them
|
|
WO2012000104A1
(en)
|
2010-06-30 |
2012-01-05 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
|
HUE026646T2
(en)
|
2010-07-06 |
2016-07-28 |
Glaxosmithkline Biologicals Sa |
Preferred liposomes containing lipids of PKA value for delivery of RNA
|
|
US9770463B2
(en)
|
2010-07-06 |
2017-09-26 |
Glaxosmithkline Biologicals Sa |
Delivery of RNA to different cell types
|
|
PL2591114T3
(pl)
|
2010-07-06 |
2017-08-31 |
Glaxosmithkline Biologicals Sa |
Immunizacja dużych ssaków małymi dawkami rna
|
|
HUE047796T2
(hu)
|
2010-07-06 |
2020-05-28 |
Glaxosmithkline Biologicals Sa |
RNS bevitele több immunútvonal bekapcsolására
|
|
CA2801523C
(en)
|
2010-07-30 |
2021-08-03 |
Curevac Gmbh |
Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
|
|
WO2012019630A1
(en)
|
2010-08-13 |
2012-02-16 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
|
|
RS63890B1
(sr)
|
2010-08-31 |
2023-02-28 |
Glaxosmithkline Biologicals Sa |
Mali lipozomi za isporuku rnk koja kodira imunogen
|
|
ES2727583T3
(es)
|
2010-08-31 |
2019-10-17 |
Glaxosmithkline Biologicals Sa |
Lípidos adecuados para la administración liposómica de ARN que codifica proteínas
|
|
PT3970742T
(pt)
|
2010-08-31 |
2022-06-27 |
Glaxosmithkline Biologicals Sa |
Lipossomas peguilados para entrega de arn codificador de imunogénio
|
|
RU2013120302A
(ru)
|
2010-10-01 |
2014-11-20 |
Модерна Терапьютикс, Инк. |
Сконструированные нуклеиновые кислоты и способы их применения
|
|
WO2012089225A1
(en)
|
2010-12-29 |
2012-07-05 |
Curevac Gmbh |
Combination of vaccination and inhibition of mhc class i restricted antigen presentation
|
|
WO2012116715A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in newborns and infants
|
|
WO2012113413A1
(en)
|
2011-02-21 |
2012-08-30 |
Curevac Gmbh |
Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
|
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
|
EP2691101A2
(en)
|
2011-03-31 |
2014-02-05 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
EP3354644A1
(en)
|
2011-06-08 |
2018-08-01 |
Translate Bio, Inc. |
Cleavable lipids
|
|
US20140141070A1
(en)
|
2011-07-06 |
2014-05-22 |
Andrew Geall |
Liposomes having useful n:p ratio for delivery of rna molecules
|
|
EP3508220A1
(en)
|
2011-08-31 |
2019-07-10 |
GlaxoSmithKline Biologicals S.A. |
Pegylated liposomes for delivery of immunogen-encoding rna
|
|
WO2013035563A1
(ja)
|
2011-09-08 |
2013-03-14 |
株式会社トクヤマ |
界面活性剤被覆半水石膏およびその製造方法
|
|
RU2648950C2
(ru)
|
2011-10-03 |
2018-04-02 |
Модерна Терапьютикс, Инк. |
Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
|
|
WO2013059475A1
(en)
|
2011-10-18 |
2013-04-25 |
Life Technologies Corporation |
Alkynyl-derivatized cap analogs, preparation and uses thereof
|
|
CN104114572A
(zh)
|
2011-12-16 |
2014-10-22 |
现代治疗公司 |
经修饰的核苷、核苷酸和核酸组合物
|
|
WO2013113325A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Negatively charged nucleic acid comprising complexes for immunostimulation
|
|
WO2013113326A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
|
|
EP2623121A1
(en)
|
2012-01-31 |
2013-08-07 |
Bayer Innovation GmbH |
Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
|
|
WO2013120500A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
|
|
WO2013120499A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
|
|
WO2013120498A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
|
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
|
SG10201607962RA
(en)
|
2012-03-27 |
2016-11-29 |
Curevac Ag |
Artificial nucleic acid molecules
|
|
WO2013143700A2
(en)
|
2012-03-27 |
2013-10-03 |
Curevac Gmbh |
Artificial nucleic acid molecules comprising a 5'top utr
|
|
RU2658490C2
(ru)
|
2012-03-27 |
2018-06-21 |
Кьюрвак Аг |
Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов
|
|
AU2013243948A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins associated with human disease
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
WO2013174409A1
(en)
|
2012-05-25 |
2013-11-28 |
Curevac Gmbh |
Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
|
|
RU2718988C2
(ru)
|
2013-02-22 |
2020-04-15 |
Куревак Аг |
Комбинация противораковой рнк-вакцины и ингибитора пути pd-1 и ее применение
|
|
WO2014160243A1
(en)
|
2013-03-14 |
2014-10-02 |
The Trustees Of The University Of Pennsylvania |
Purification and purity assessment of rna molecules synthesized with modified nucleosides
|
|
BR112016001192A2
(pt)
|
2013-08-21 |
2017-08-29 |
Curevac Ag |
Vacina contra a raiva
|
|
DK3035955T3
(da)
|
2013-08-21 |
2019-12-02 |
Curevac Ag |
Sammensætning og vaccine til behandling af lungekræft
|
|
WO2015024664A1
(en)
|
2013-08-21 |
2015-02-26 |
Curevac Gmbh |
Composition and vaccine for treating prostate cancer
|
|
AU2014310935B2
(en)
|
2013-08-21 |
2019-11-21 |
CureVac SE |
Combination vaccine
|
|
BR112016003361A2
(pt)
|
2013-08-21 |
2017-11-21 |
Curevac Ag |
vacina do vírus sincicial respiratório (rsv)
|
|
SG11201510747RA
(en)
|
2013-08-21 |
2016-03-30 |
Curevac Ag |
Method for increasing expression of rna-encoded proteins
|
|
ES2806575T3
(es)
|
2013-11-01 |
2021-02-18 |
Curevac Ag |
ARN modificado con propiedades inmunoestimuladoras disminuidas
|
|
SG11201604198YA
(en)
|
2013-12-30 |
2016-07-28 |
Curevac Ag |
Methods for rna analysis
|
|
CA2927254C
(en)
|
2013-12-30 |
2023-10-24 |
Curevac Ag |
Artificial nucleic acid molecules
|
|
KR102399799B1
(ko)
|
2013-12-30 |
2022-05-18 |
큐어백 아게 |
인공 핵산 분자
|
|
WO2015135558A1
(en)
|
2014-03-12 |
2015-09-17 |
Curevac Gmbh |
Combination of vaccination and ox40 agonists
|
|
CA2936286A1
(en)
|
2014-04-01 |
2015-10-08 |
Curevac Ag |
Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
|
|
SG10201912038TA
(en)
|
2014-04-23 |
2020-02-27 |
Modernatx Inc |
Nucleic acid vaccines
|
|
PT3134506T
(pt)
|
2014-04-25 |
2019-10-31 |
Translate Bio Inc |
Métodos de purificação de rna mensageiro
|
|
US10837039B2
(en)
|
2014-06-10 |
2020-11-17 |
Curevac Real Estate Gmbh |
Methods and means for enhancing RNA production
|
|
SMT202200502T1
(it)
|
2014-06-25 |
2023-01-13 |
Acuitas Therapeutics Inc |
Nuovi lipidi e formulazioni di nanoparticelle lipidiche per l'erogazione di acidi nucleici
|
|
WO2016022914A1
(en)
|
2014-08-08 |
2016-02-11 |
Moderna Therapeutics, Inc. |
Compositions and methods for the treatment of ophthalmic diseases and conditions
|
|
DK3204399T3
(da)
|
2014-10-09 |
2025-02-24 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Lange poly (a)-plasmider og fremgangsmåder til indføring af lange poly (a)-sekvenser i plasmidet
|
|
DE202015010000U1
(de)
|
2014-12-12 |
2023-07-03 |
CureVac SE |
Artifizielle Nukleinsäuremoleküle für eine verbesserte Proteinexpression
|
|
CA2962849A1
(en)
|
2014-12-16 |
2016-06-23 |
Curevac Ag |
Ebolavirus and marburgvirus vaccines
|
|
US20160188710A1
(en)
|
2014-12-29 |
2016-06-30 |
Wipro Limited |
METHOD AND SYSTEM FOR MIGRATING DATA TO NOT ONLY STRUCTURED QUERY LANGUAGE (NoSOL) DATABASE
|
|
KR102580696B1
(ko)
|
2014-12-30 |
2023-09-19 |
큐어백 에스이 |
신규 인공 핵산 분자
|
|
EP3283059B1
(en)
|
2015-04-13 |
2024-01-03 |
CureVac Manufacturing GmbH |
Method for producing rna compositions
|
|
SG11201707663SA
(en)
|
2015-04-17 |
2017-11-29 |
Curevac Ag |
Lyophilization of rna
|
|
RU2749113C2
(ru)
|
2015-04-22 |
2021-06-04 |
Куревак Аг |
Содержащая рнк композиция для лечения опухолевых заболеваний
|
|
US20180303925A1
(en)
|
2015-04-27 |
2018-10-25 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-Modified RNA For Inducing an Adaptive Immune Response
|
|
US20180208957A1
(en)
|
2015-04-30 |
2018-07-26 |
Curevac Ag |
Method for in vitro transcription using an immobilized restriction enzyme
|
|
ES2897823T3
(es)
|
2015-04-30 |
2022-03-02 |
Curevac Ag |
Poli(N)polimerasa inmovilizada
|
|
DK3294885T3
(da)
|
2015-05-08 |
2020-08-10 |
Curevac Real Estate Gmbh |
Fremgangsmåde til at fremstille rna
|
|
KR20180004820A
(ko)
|
2015-05-15 |
2018-01-12 |
큐어백 아게 |
적어도 하나의 mRNA 구성의 투여를 포함하는 신규 프라임-부스트 요법
|
|
EP3297682B1
(en)
|
2015-05-20 |
2021-07-14 |
CureVac AG |
Dry powder composition comprising long-chain rna
|
|
WO2016184575A1
(en)
|
2015-05-20 |
2016-11-24 |
Curevac Ag |
Dry powder composition comprising long-chain rna
|
|
PL4108769T3
(pl)
|
2015-05-29 |
2024-02-05 |
CureVac Manufacturing GmbH |
Sposób wytwarzania i oczyszczania rna obejmujący co najmniej jeden etap filtracji o przepływie stycznym
|
|
EP4098743A1
(en)
|
2015-05-29 |
2022-12-07 |
CureVac AG |
Method for adding cap structures to rna using immobilized enzymes
|
|
US20180296663A1
(en)
|
2015-06-17 |
2018-10-18 |
Curevac Ag |
Vaccine composition
|
|
LT3313829T
(lt)
|
2015-06-29 |
2024-08-12 |
Acuitas Therapeutics Inc. |
Lipidai ir lipidų nanodalelių sudėtys, skirtos nukleorūgščių tiekimui
|
|
US20190017100A1
(en)
|
2015-07-01 |
2019-01-17 |
Curevac Ag |
Method for analysis of an rna molecule
|
|
WO2017009376A1
(en)
|
2015-07-13 |
2017-01-19 |
Curevac Ag |
Method of producing rna from circular dna and corresponding template dna
|
|
WO2017021546A1
(en)
|
2015-08-05 |
2017-02-09 |
Curevac Ag |
Epidermal mrna vaccine
|
|
DK3332019T3
(da)
|
2015-08-07 |
2020-02-17 |
Curevac Ag |
Fremgangsmåde til in vivo-produktionen af rna i en værtscelle
|
|
WO2017025447A1
(en)
|
2015-08-10 |
2017-02-16 |
Curevac Ag |
Method of increasing the replication of a circular dna molecule
|
|
CA2992801A1
(en)
|
2015-08-28 |
2017-03-09 |
Curevac Ag |
Artificial nucleic acid molecules
|
|
EP4286012A3
(en)
|
2015-09-17 |
2024-05-29 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
WO2017046801A1
(en)
|
2015-09-17 |
2017-03-23 |
Ramot At Tel-Aviv University Ltd. |
Coronaviruses epitope-based vaccines
|
|
ES2964690T3
(es)
|
2015-09-21 |
2024-04-09 |
Trilink Biotechnologies Llc |
Método para sintetizar ARN con caperuza 5'
|
|
US11225682B2
(en)
|
2015-10-12 |
2022-01-18 |
Curevac Ag |
Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
|
|
WO2017066782A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Hydrophobic mrna cap analogs
|
|
WO2017066781A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified phosphate linkage
|
|
WO2017066791A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Sugar substituted mrna cap analogs
|
|
JP2018530587A
(ja)
|
2015-10-16 |
2018-10-18 |
モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． |
ｍＲＮＡキャップ類似体およびｍＲＮＡキャッピングの方法
|
|
WO2017066789A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified sugar
|
|
US11866754B2
(en)
|
2015-10-16 |
2024-01-09 |
Modernatx, Inc. |
Trinucleotide mRNA cap analogs
|
|
TW201729835A
(zh)
|
2015-10-22 |
2017-09-01 |
現代公司 |
呼吸道病毒疫苗
|
|
IL307179A
(en)
|
2015-10-28 |
2023-11-01 |
Acuitas Therapeutics Inc |
Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
US11413346B2
(en)
|
2015-11-09 |
2022-08-16 |
Curevac Ag |
Rotavirus vaccines
|
|
EP3374504B1
(en)
|
2015-11-09 |
2025-03-19 |
CureVac SE |
Optimized nucleic acid molecules
|
|
US20180371392A1
(en)
|
2015-12-21 |
2018-12-27 |
Curevac Ag |
Inlay for a culture plate and corresponding method for preparing a culture plate system with such inlay
|
|
EP3701963A1
(en)
|
2015-12-22 |
2020-09-02 |
CureVac AG |
Method for producing rna molecule compositions
|
|
EP3394280A1
(en)
|
2015-12-23 |
2018-10-31 |
CureVac AG |
Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
|
|
EP3414340B1
(en)
|
2016-02-12 |
2023-08-09 |
CureVac SE |
Method for analyzing rna
|
|
WO2017140345A1
(en)
|
2016-02-15 |
2017-08-24 |
Curevac Ag |
Method for analyzing by-products of rna in vitro transcription
|
|
US11723967B2
(en)
|
2016-02-17 |
2023-08-15 |
CureVac SE |
Zika virus vaccine
|
|
EP3423595A1
(en)
|
2016-03-03 |
2019-01-09 |
CureVac AG |
Rna analysis by total hydrolysis
|
|
US20190177714A1
(en)
|
2016-03-24 |
2019-06-13 |
Curevac Ag |
Immobilized inorganic pyrophosphatase (ppase)
|
|
EP3777881A1
(en)
|
2016-04-22 |
2021-02-17 |
CureVac AG |
Rna encoding a tumor antigen
|
|
WO2017186928A1
(en)
|
2016-04-29 |
2017-11-02 |
Curevac Ag |
Rna encoding an antibody
|
|
EP4233898A3
(en)
|
2016-05-04 |
2023-11-01 |
CureVac SE |
Influenza mrna vaccines
|
|
EP3452101A2
(en)
|
2016-05-04 |
2019-03-13 |
CureVac AG |
Rna encoding a therapeutic protein
|
|
EP4631970A3
(en)
|
2016-05-04 |
2026-01-07 |
CureVac SE |
Nucleic acid molecules and uses thereof
|
|
US20180126003A1
(en)
|
2016-05-04 |
2018-05-10 |
Curevac Ag |
New targets for rna therapeutics
|
|
WO2017203008A1
(en)
|
2016-05-25 |
2017-11-30 |
Curevac Ag |
Novel biomarkers
|
|
WO2017212007A1
(en)
|
2016-06-09 |
2017-12-14 |
Curevac Ag |
Cationic carriers for nucleic acid delivery
|
|
WO2017212008A1
(en)
|
2016-06-09 |
2017-12-14 |
Curevac Ag |
Hybrid carriers for nucleic acid cargo
|
|
WO2017212006A1
(en)
|
2016-06-09 |
2017-12-14 |
Curevac Ag |
Hybrid carriers for nucleic acid cargo
|
|
WO2017212009A1
(en)
|
2016-06-09 |
2017-12-14 |
Curevac Ag |
Hybrid carriers for nucleic acid cargo
|
|
MX2019001920A
(es)
|
2016-08-19 |
2019-07-01 |
Curevac Ag |
Arn la terapia contra el cancer.
|
|
CN116837052A
(zh)
|
2016-09-14 |
2023-10-03 |
摩登纳特斯有限公司 |
高纯度rna组合物及其制备方法
|
|
FR3056365A1
(fr)
|
2016-09-19 |
2018-03-23 |
Stmicroelectronics Sa |
Procede de gestion du fonctionnement d'un circuit de bascule synchrone de retention de faible complexite, et circuit correspondant
|
|
US10487105B2
(en)
|
2016-10-19 |
2019-11-26 |
Arcturus Therapeutics, Inc. |
Trinucleotide MRNA cap analogs
|
|
EP4599847A3
(en)
|
2016-10-25 |
2025-11-12 |
Trustees of Dartmouth College |
Prefusion coronavirus spike proteins and their use
|
|
BR112019008481A2
(pt)
|
2016-10-26 |
2020-03-03 |
Curevac Ag |
Vacinas de mrna de nanopartículas lipídicas
|
|
ES3063077T3
(en)
|
2016-10-26 |
2026-04-15 |
Acuitas Therapeutics Inc |
Lipid nanoparticle formulations
|
|
US11279923B2
(en)
|
2016-11-28 |
2022-03-22 |
Curevac Ag |
Method for purifying RNA
|
|
WO2018104540A1
(en)
|
2016-12-08 |
2018-06-14 |
Curevac Ag |
Rnas for wound healing
|
|
EP3551230A1
(en)
|
2016-12-08 |
2019-10-16 |
CureVac AG |
Rna for treatment or prophylaxis of a liver disease
|
|
WO2018115525A1
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Lassa virus vaccine
|
|
EP3558355A2
(en)
|
2016-12-23 |
2019-10-30 |
CureVac AG |
Henipavirus vaccine
|
|
EP3558356A2
(en)
|
2016-12-23 |
2019-10-30 |
CureVac AG |
Mers coronavirus vaccine
|
|
CA3050614A1
(en)
|
2017-03-17 |
2018-09-20 |
Curevac Ag |
Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
|
|
MA47790A
(fr)
|
2017-03-17 |
2021-05-05 |
Modernatx Inc |
Vaccins à base d'arn contre des maladies zoonotiques
|
|
AU2018240515B2
(en)
|
2017-03-24 |
2024-07-25 |
CureVac SE |
Nucleic acids encoding CRISPR-associated proteins and uses thereof
|
|
WO2018211038A1
(en)
|
2017-05-17 |
2018-11-22 |
Curevac Ag |
Method for determining at least one quality parameter of an rna sample
|
|
US10724437B2
(en)
|
2017-06-28 |
2020-07-28 |
General Electric Company |
Systems and methods for particle separator in a gas turbine engine
|
|
RU2020103379A
(ru)
|
2017-07-04 |
2021-08-04 |
Куревак Аг |
Новые молекулы нуклеиновых кислот
|
|
US11602557B2
(en)
|
2017-08-22 |
2023-03-14 |
Cure Vac SE |
Bunyavirales vaccine
|
|
CN111630173A
(zh)
|
2017-10-19 |
2020-09-04 |
库瑞瓦格股份公司 |
新型人工核酸分子
|
|
EP3707271A1
(en)
|
2017-11-08 |
2020-09-16 |
CureVac AG |
Rna sequence adaptation
|
|
EP3728634A1
(en)
|
2017-12-21 |
2020-10-28 |
CureVac AG |
Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
|
|
WO2019193183A2
(en)
|
2018-04-05 |
2019-10-10 |
Curevac Ag |
Novel yellow fever nucleic acid molecules for vaccination
|
|
CA3091558A1
(en)
|
2018-04-17 |
2019-10-24 |
Curevac Ag |
Novel rsv rna molecules and compositions for vaccination
|
|
JP7384832B2
(ja)
|
2018-05-16 |
2023-11-21 |
トランスレイト バイオ， インコーポレイテッド |
リボースカチオン性脂質
|
|
CN112437767B
(zh)
|
2018-05-24 |
2023-10-27 |
川斯勒佰尔公司 |
硫酯阳离子脂质
|
|
WO2019232095A1
(en)
|
2018-05-30 |
2019-12-05 |
Translate Bio, Inc. |
Vitamin cationic lipids
|
|
CA3101484A1
(en)
|
2018-05-30 |
2019-12-05 |
Translate Bio, Inc. |
Phosphoester cationic lipids
|
|
JP7463006B2
(ja)
|
2018-05-30 |
2024-04-08 |
トランスレイト バイオ， インコーポレイテッド |
ステロイド性部分を含むカチオン性脂質
|
|
WO2020002525A1
(en)
|
2018-06-27 |
2020-01-02 |
Curevac Ag |
Novel lassa virus rna molecules and compositions for vaccination
|
|
BR112020025601A8
(pt)
|
2018-06-28 |
2022-07-05 |
Tesla Automation GmbH |
Biorreator para a transcrição in vitro de rna
|
|
US12492425B2
(en)
|
2018-12-21 |
2025-12-09 |
CureVac SE |
Methods for RNA analysis
|
|
CA3118034A1
(en)
|
2018-12-21 |
2020-06-25 |
Curevac Ag |
Rna for malaria vaccines
|
|
US10745919B1
(en)
|
2019-07-26 |
2020-08-18 |
Big Time Investment, Llc |
Method and apparatus for installing a staircase assembly into a building
|
|
US20230097090A1
(en)
|
2019-08-14 |
2023-03-30 |
Acuitas Therapeutics, Inc. |
Improved lipid nanoparticles for delivery of nucleic acids
|
|
CN110647053A
(zh)
|
2019-09-19 |
2020-01-03 |
北京智行者科技有限公司 |
一种自动驾驶仿真方法及系统
|
|
KR20220121246A
(ko)
|
2019-12-20 |
2022-08-31 |
큐어백 아게 |
핵산 전달용 신규한 지질 나노입자
|
|
KR20220150276A
(ko)
|
2020-01-11 |
2022-11-10 |
시벡 바이오테크놀로지스, 엘엘씨 |
진핵생물로의 진핵생물-번역가능한 mRNA의 생산 및 전달을 위한 미생물 시스템
|
|
WO2021147025A1
(en)
|
2020-01-22 |
2021-07-29 |
The University Of Hong Kong-Shenzhen Hospital |
Anti 2019-ncov vaccine
|
|
US12312376B2
(en)
|
2020-01-24 |
2025-05-27 |
Aim Immunotech Inc. |
Therapeutic double stranded RNA and methods for producing the same
|
|
US10953089B1
(en)
|
2020-01-27 |
2021-03-23 |
Novavax, Inc. |
Coronavirus vaccine formulations
|
|
BR112022014737A2
(pt)
|
2020-01-27 |
2022-12-20 |
Valent Usa Llc |
Composição aquosa, e, método para controlar uma praga
|
|
US20210228707A1
(en)
|
2020-01-28 |
2021-07-29 |
Modernatx, Inc. |
Coronavirus rna vaccines
|
|
JP2023511633A
(ja)
|
2020-01-28 |
2023-03-20 |
モデルナティエックス インコーポレイテッド |
コロナウイルスｒｎａワクチン
|
|
AU2021213121A1
(en)
|
2020-01-28 |
2022-08-18 |
Codagenix Inc. |
Deoptimized SARS-CoV-2 and methods and uses thereof
|
|
TW202204380A
(zh)
|
2020-01-31 |
2022-02-01 |
美商詹森藥物公司 |
用於預防及治療冠狀病毒感染之組合物及方法－sars-cov-2疫苗
|
|
WO2021155760A1
(zh)
|
2020-02-03 |
2021-08-12 |
康希诺生物股份公司 |
用于2019-nCoV型冠状病毒mRNA疫苗、制备方法及其应用
|
|
US11241493B2
(en)
*
|
2020-02-04 |
2022-02-08 |
Curevac Ag |
Coronavirus vaccine
|
|
MX2022009460A
(es)
|
2020-02-04 |
2022-12-16 |
Curevac Ag |
Vacuna contra el coronavirus.
|
|
US12194089B2
(en)
*
|
2020-02-04 |
2025-01-14 |
CureVac SE |
Coronavirus vaccine
|
|
CN111821433B
(zh)
|
2020-02-06 |
2021-06-08 |
深圳市瑞吉生物科技有限公司 |
mRNA疫苗及其合成方法、试剂盒
|
|
JP7438604B2
(ja)
|
2020-02-07 |
2024-02-27 |
モデルナティエックス インコーポレイテッド |
ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン
|
|
EP4085131A4
(en)
|
2020-02-10 |
2024-03-13 |
Versitech Limited |
AGAINST THE SARS-CORONAVIRUS 2 IMMUNOGENE COMPOSITIONS, METHOD FOR THEIR PRODUCTION AND THEIR USE
|
|
MX2022009836A
(es)
|
2020-02-11 |
2022-11-30 |
Us Health |
Vacuna para sars-cov-2.
|
|
CN116113424A
(zh)
|
2020-02-11 |
2023-05-12 |
赛托纳斯治疗公司 |
快速疫苗平台
|
|
AU2021219847A1
(en)
|
2020-02-12 |
2022-10-13 |
Massachusetts Institute Of Technology |
Field deployable CRISPR-Cas diagnostics and methods of use thereof
|
|
WO2021163371A1
(en)
|
2020-02-12 |
2021-08-19 |
La Jolla Institute For Immunology |
Coronavirus t cell epitopes and uses thereof
|
|
CN113186203B
(zh)
|
2020-02-13 |
2022-12-30 |
斯微(上海)生物科技股份有限公司 |
治疗或者预防冠状病毒病的疫苗试剂
|
|
CA3166811A1
(en)
|
2020-02-13 |
2021-08-19 |
Nicolas Robert Xavier Escriou |
Measles-vectored covid-19 immunogenic compositions and vaccines
|
|
WO2021160346A1
(en)
|
2020-02-13 |
2021-08-19 |
Institut Pasteur |
Nucleic acid vaccine against the sars-cov-2 coronavirus
|
|
GB202004007D0
(en)
|
2020-03-19 |
2020-05-06 |
Immodulon Therapeutics Ltd |
Coronavirus
|
|
EP4103233A4
(en)
|
2020-02-14 |
2025-03-26 |
Epivax, Inc. |
T-CELL EPITOPES AND ASSOCIATED COMPOSITIONS FOR THE PREVENTION, DIAGNOSIS AND TREATMENT OF COVID-19
|
|
KR20230004447A
(ko)
|
2020-02-14 |
2023-01-06 |
이더알엔에이 이뮤노테라피스 엔브이 |
비강 내 mRNA 백신
|
|
JP2023513611A
(ja)
|
2020-02-14 |
2023-03-31 |
ゲオバックス インコーポレイテッド |
Ｓａｒｓ－ｃｏｖ２に対する免疫応答を誘導するためのワクチン及びその利用
|
|
CA3167833A1
(en)
|
2020-02-14 |
2021-08-19 |
Bertrand Victor Gilbert GEORGES |
Coronavirus immunogenic compositions and uses thereof
|
|
EP4103230A1
(en)
|
2020-02-14 |
2022-12-21 |
University of Washington |
Polypeptides, compositions, and their use to treat or limit development of an infection
|
|
CN111228475A
(zh)
|
2020-02-21 |
2020-06-05 |
赛诺（深圳）生物医药研究有限公司 |
用于预防新型冠状病毒的生物制品
|
|
WO2021000968A2
(zh)
|
2020-02-23 |
2021-01-07 |
广州恩宝生物医药科技有限公司 |
一种用于预防SARS-CoV-2感染的腺病毒载体疫苗
|
|
CN112300251B
(zh)
|
2020-02-24 |
2022-04-05 |
成都威斯克生物医药有限公司 |
抗SARS-CoV-2感染的蛋白及疫苗
|
|
CN111333704B
(zh)
|
2020-02-24 |
2021-01-12 |
军事科学院军事医学研究院微生物流行病研究所 |
新型冠状病毒covid-19疫苗、制备方法及其应用
|
|
US20230181715A1
(en)
|
2020-03-31 |
2023-06-15 |
Raffael NACHBAGAUER |
Universal Influenza Vaccine Using Nucleoside-Modified mRNA
|
|
CN111647053A
(zh)
|
2020-04-16 |
2020-09-11 |
军事科学院军事医学研究院生命组学研究所 |
多肽及其在新型冠状病毒检测、抗体或疫苗筛选中的应用
|
|
WO2021209970A1
(en)
|
2020-04-16 |
2021-10-21 |
Glaxosmithkline Biologicals Sa |
Sars cov-2 spike protein construct
|
|
IL297414A
(en)
|
2020-04-22 |
2022-12-01 |
Pfizer |
Vaccine against the corona virus
|
|
EP3901261A1
(en)
|
2020-04-22 |
2021-10-27 |
BioNTech RNA Pharmaceuticals GmbH |
Coronavirus vaccine
|
|
WO2021222304A1
(en)
|
2020-04-27 |
2021-11-04 |
Modernatx, Inc. |
Sars-cov-2 rna vaccines
|
|
MX2022014162A
(es)
|
2020-05-11 |
2023-02-23 |
Janssen Pharmaceuticals Inc |
Proteínas de fusión de la proteína de la espícula del coronavirus estabilizadas.
|
|
CN112695057B
(zh)
|
2020-05-11 |
2022-04-26 |
广东珩达生物医药科技有限公司 |
Sars-cov-2抗原多肽及其重组腺相关病毒和在制备疫苗中的应用
|
|
CN116437951A
(zh)
|
2020-05-19 |
2023-07-14 |
磨石生物公司 |
Sars-cov-2疫苗
|
|
CN111606980B
(zh)
|
2020-05-27 |
2021-10-26 |
中国医学科学院基础医学研究所 |
Sars-cov冠状病毒s2蛋白多肽及其应用
|
|
CN111606981B
(zh)
|
2020-05-27 |
2022-02-08 |
中国医学科学院基础医学研究所 |
Sars-cov冠状病毒s1蛋白多肽及其应用
|
|
WO2021242294A1
(en)
|
2020-05-28 |
2021-12-02 |
Sotira Covid, Llc |
Peptides for covid-19 prevention and treatment
|
|
EP4157345A4
(en)
|
2020-05-29 |
2024-09-11 |
Board of Regents, The University of Texas System |
GENETICALLY MODIFIED CORONAVIRUS SPIKE(S) PROTEIN AND METHODS OF USE THEREOF
|
|
US20230234992A1
(en)
|
2020-06-05 |
2023-07-27 |
Glaxosmithkline Biologicals Sa |
Modified betacoronavirus spike proteins
|
|
CN111732638B
(zh)
|
2020-07-02 |
2022-01-25 |
重庆博唯佰泰生物制药有限公司 |
一种针对SARS-CoV-2的疫苗
|
|
CN111778264B
(zh)
|
2020-07-14 |
2021-06-29 |
广州佰芮慷生物科技有限公司 |
基于新型腺病毒载体Sad23L和/或Ad49L的新型冠状病毒肺炎疫苗
|
|
CN112390863B
(zh)
|
2020-09-23 |
2022-11-01 |
厚朴生物科技（苏州）有限公司 |
改造的新冠病毒Spike蛋白胞外结构域及其应用
|
|
EP4217371A1
(en)
|
2020-09-25 |
2023-08-02 |
ModernaTX, Inc. |
Multi-proline-substituted coronavirus spike protein vaccines
|
|
CN112266411B
(zh)
|
2020-09-25 |
2022-06-24 |
北京诺思兰德生物技术股份有限公司 |
一种新型冠状病毒疫苗及其应用
|
|
CN112226445B
(zh)
|
2020-10-20 |
2021-05-11 |
成都欧林生物科技股份有限公司 |
编码SARS-CoV-2病毒刺突蛋白的核酸及其的应用
|
|
WO2022110099A1
(en)
|
2020-11-30 |
2022-06-02 |
Guangzhou Argorna Biopharmaceuticals Co., Ltd. |
Coronavirus vaccines and uses thereof
|
|
EP4277655A1
(en)
|
2021-01-15 |
2023-11-22 |
ModernaTX, Inc. |
Variant strain-based coronavirus vaccines
|
|
JP2024503699A
(ja)
|
2021-01-15 |
2024-01-26 |
モデルナティエックス インコーポレイテッド |
バリアント株ベースのコロナウイルスワクチン
|
|
WO2022180219A1
(en)
|
2021-02-25 |
2022-09-01 |
Kosmatopoulos Kostantinos Kostas |
Optimized vaccine to elicit a t cell immunity against sars-cov-2
|
|
WO2023051701A1
(zh)
|
2021-09-29 |
2023-04-06 |
成都威斯津生物医药科技有限公司 |
抗SARS-CoV-2感染的mRNA、蛋白以及抗SARS-CoV-2感染的疫苗
|
|
US20250134987A1
(en)
|
2021-10-15 |
2025-05-01 |
Yale University |
Compositions and methods for vaccination against pathogenic coronavirus species and variants
|
|
WO2023086961A1
(en)
|
2021-11-12 |
2023-05-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Sars-cov-2 spike fused to a hepatitis b surface antigen
|